EP0971916A1 - N-(arginyl)benzensulfonamidderivate und ihre verwendung als antithrombotische mittel - Google Patents
N-(arginyl)benzensulfonamidderivate und ihre verwendung als antithrombotische mittelInfo
- Publication number
- EP0971916A1 EP0971916A1 EP98914932A EP98914932A EP0971916A1 EP 0971916 A1 EP0971916 A1 EP 0971916A1 EP 98914932 A EP98914932 A EP 98914932A EP 98914932 A EP98914932 A EP 98914932A EP 0971916 A1 EP0971916 A1 EP 0971916A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- formula
- compound
- straight
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to and derivatives of 5 N- (arginyl) benzenesulphonamide, their preparation and their therapeutic application.
- R 3 represents either a hydrogen atom or a (C 1 -C 5 ) straight or branched alkyl group, or a group -C0R 5 where R 5 is a (C 1 -C 4 ) straight or branched alkyl group, - (CH 2 ) n OCH 3 , -CH 2 0 (C 2 H 4 0) n CH 3; - (CH 2 ) n CF 3 , - (CH 2 ) n 0H (n equal 1 to 4), either a group -S0 2 R 6 , or a group -CONHR 6 , or a group
- the ratio (x: y) represents the ratio (acid: base).
- reaction medium The temperature of the reaction medium is allowed to return to ambient temperature and stirring is continued for 18 hours at this temperature. Evaporated under reduced pressure and the aqueous phase is extracted with 2 times 300 ml of ethyl acetate. The organic phases are combined and washed with 100 ml of a saturated sodium chloride solution. It is dried over sodium sulfate and concentrated under reduced pressure. The residue thus obtained is purified by chromatography on a column of silica gel, eluting with a cyclohexane: ethyl acetate mixture (9: 1).
- the residue is taken up in 150 ml of ethyl acetate and washed successively with 100 ml of an aqueous 0.1N hydrochloric acid solution, 50 ml of a saturated solution of sodium hydrogencarbonate and 50 ml of a saturated solution of sodium chloride. It is dried over sodium sulfate and concentrated under reduced pressure.
- the residue is purified by chromatography on a column of silica gel, eluting with a dichloromethane: methanol mixture (98: 2).
- the mixture is heated at 50 ° C. for 0.5 hour under a pressure of 0.35 MPa (50 psi) a mixture of 0.75 g (0.9 mmol) of (S) - [4- [(4-ethylpiperidin- l-yl) carbonyl] -4- [[[2 '-fluoro-2- [(1- oxopropyl) amino] [1,1' -biphenyl] -3-yl] sulfonyl] amino] butyl] [imino [[ (phenylmethoxy) carbonyl] amino] methyl] phenylmethyl carbamate and 0.8 g of 10% palladium on carbon in 10 ml of water and 10 ml of acetic acid.
- the temperature of the mixture is allowed to return to ambient temperature, it is stirred for 18 hours at this temperature and concentrated under reduced pressure.
- the residue is taken up in 100 ml of 7 ethyl acetate and washed successively with twice 50 ml of 0.5N hydrochloric acid, 50 ml of a saturated solution of sodium hydrogen carbonate and 50 ml of a saturated sodium chloride solution. It is dried over sodium sulfate, filtered and concentrated under reduced pressure.
- the residue is taken up in 50 ml of tetrahydrofuran and treated for 15 minutes at 0 ° C. with a stream of gaseous ammonia. The temperature is allowed to return to room temperature, stirring is continued for 2 hours and concentrated under reduced pressure.
- the temperature of the reaction medium is allowed to return to ambient temperature, stirring is continued for 15 hours at this temperature and concentration is carried out under reduced pressure.
- the residue is taken up in 100 ml of ethyl acetate, washed twice with 50 ml of 1N hydrochloric acid and then with 50 ml of a saturated solution of sodium chloride, dried over sodium sulfate, filtered. and concentrated under reduced pressure.
- the temperature of the reaction medium is allowed to return to ambient temperature, stirring is continued for 16 hours at this temperature and concentration is carried out under reduced pressure.
- the residue is taken up in 100 ml of ethyl acetate, washed successively with 30 ml of 1N hydrochloric acid, 20 ml of water, 30 ml of a saturated solution of sodium hydrogen carbonate and then with 20 ml of saturated sodium chloride solution, dried over sodium sulfate, filtered and concentrated under reduced pressure.
- the temperature of the mixture is allowed to return to ambient temperature and stirring is continued for 18 hours at this temperature.
- the reaction medium is cooled to 0 ° C., acidified to pH 2 with a 12N aqueous hydrochloric acid solution and then neutralized with a solution of sodium hydrogencarbonate before adding 2.4 g (11 mmol) of bis (1, 1-dimethylethyl) dicarbonate dissolved in 15 ml of methanol.
- the temperature of the mixture is allowed to return to room temperature, stirring is continued for 18 hours at this temperature and concentrated under reduced pressure.
- the residue is taken up in 200 ml of ethyl acetate, washed with 50 ml of a saturated sodium chloride solution, dried over sodium sulphate and concentrated again under reduced pressure.
- the residue thus obtained is purified by chromatography on a column of silica gel, eluting with a cyclohexane: ethyl acetate mixture (7: 3).
- the reaction medium is left under stirring at this temperature for 6 hours and concentrated under reduced pressure.
- the residue is purified by chromatography on a column of silica gel, eluting with a cyclohexane: ethyl acetate mixture (1: 1).
- reaction medium The temperature of the reaction medium is allowed to return to ambient temperature, stirring is continued for 30 minutes at this temperature and evaporated to dryness.
- the residue is taken up in 250 ml of toluene and evaporated to dryness. It is taken up in 200 ml of toluene and evaporated to dryness.
- the residue is purified by chromatography on a column of silica gel, eluting with a dichloromethane: methanol mixture (99.5: 0.5).
- HC1 corresponds to a hydrochloride and the ratio between brackets is the ratio (help: base); the absence of any mention means that the compound is in the base form.
- - c 0.2; methanol except for compounds n ° 11, 12, 13, 14, 18, 19, 21, 23, 25, 30, 32, 33, 34, 41 and 42,
- mice Male CD rats weighing 150 to 200 g are treated with the test compound or with the vehicle, i.v., orally or subcutaneously. Then the animals are anesthetized with Nembutal TM (60 mg / kg; 0.1 ml / kg), the blood is taken on 3.8% trisodium citrate (1 vol / 9 vol of blood) at the retro sinus orbital and the plasma is prepared by centrifugation at 3600 g for 15 minutes at room temperature. 200 ⁇ l of plasma are then incubated at 37 ° C. with 200 ⁇ l of a human thrombin solution, the final concentration of human thrombin being 0.75 NIH units / ml and the coagulation time is noted. The anticoagulant effect is expressed by the dose which increases the coagulation time by 100%. They inhibit the coagulation of rat plasma at doses of 0.01 to 5 mg / kg i.v. They are also active by the oral and subcutaneous routes.
- Nembutal TM 60 mg / kg;
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9703392 | 1997-03-20 | ||
FR9703392A FR2761065B1 (fr) | 1997-03-20 | 1997-03-20 | Derives de n-(arginyle)benzenesulfonamide, leur preparation et leur application en therapeutique |
PCT/FR1998/000532 WO1998042700A1 (fr) | 1997-03-20 | 1998-03-17 | Derives de n-(arginyl)benzenesulfonamide et leur utilisation comme agents antithrombotiques |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0971916A1 true EP0971916A1 (de) | 2000-01-19 |
Family
ID=9505004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98914932A Withdrawn EP0971916A1 (de) | 1997-03-20 | 1998-03-17 | N-(arginyl)benzensulfonamidderivate und ihre verwendung als antithrombotische mittel |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0971916A1 (de) |
AR (1) | AR012096A1 (de) |
AU (1) | AU6924398A (de) |
FR (1) | FR2761065B1 (de) |
WO (1) | WO1998042700A1 (de) |
ZA (1) | ZA982355B (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2793418B1 (fr) * | 1999-05-11 | 2001-07-27 | Synthelabo | Formulations galeniques d'agents antithrombotiques pour administration sous-cutanee |
CN105707076B (zh) * | 2014-12-05 | 2018-12-14 | 沈阳中化农药化工研发有限公司 | 除草组合物及应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1131621A (en) * | 1977-01-19 | 1982-09-14 | Shosuke Okamoto | N.sup.2-arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof |
GB9505538D0 (en) * | 1995-03-18 | 1995-05-03 | Ciba Geigy Ag | New compounds |
FR2735469B1 (fr) * | 1995-06-13 | 1997-07-11 | Synthelabo | N2-(arylsulfonyl)-l-arginylpiperidin-2-carboxylates, leur preparation et leur application en therapeutique |
-
1997
- 1997-03-20 FR FR9703392A patent/FR2761065B1/fr not_active Expired - Fee Related
-
1998
- 1998-03-17 WO PCT/FR1998/000532 patent/WO1998042700A1/fr not_active Application Discontinuation
- 1998-03-17 AU AU69243/98A patent/AU6924398A/en not_active Abandoned
- 1998-03-17 EP EP98914932A patent/EP0971916A1/de not_active Withdrawn
- 1998-03-18 AR ARP980101211A patent/AR012096A1/es unknown
- 1998-03-19 ZA ZA982355A patent/ZA982355B/xx unknown
Non-Patent Citations (1)
Title |
---|
See references of WO9842700A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU6924398A (en) | 1998-10-20 |
ZA982355B (en) | 1998-09-22 |
AR012096A1 (es) | 2000-09-27 |
FR2761065A1 (fr) | 1998-09-25 |
WO1998042700A1 (fr) | 1998-10-01 |
FR2761065B1 (fr) | 2000-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW397825B (en) | Aroyl-piperidine derivatives | |
EP1497274B1 (de) | Terphenylderivate, deren herstellung und zusammensetzungen, die diese enthalten | |
EP1499589B1 (de) | N-¬phenyl(piperidin-2-yl)methyl|benzamidderivate,verfahren zu ihrer herstellung und ihre therapeutische anwendung | |
EP0307303B1 (de) | 1-[(2-Pyrimidinyl)-aminoalkyl]-piperidine, deren Herstellung und Verwendung als Heilmittel | |
EP0090733B1 (de) | Disubstituierte Polymethylen-Imine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen | |
FR2786482A1 (fr) | Nouveaux derives de 2-pyridone, leur preparation et leur application en therapeutique | |
JP2001513767A (ja) | メタロプロテアーゼ阻害剤としての逆ヒドロキサメート誘導体 | |
FR2659323A1 (fr) | Derives de 4-(aminomethyl) piperidine, leur preparation et leur application en therapeutique. | |
EP0360685B1 (de) | 1-[(Diarylmethoxy)alkyl]-pyrrolidine und -piperidine, Verfahren zu ihrer Herstellung und Arzneimittel, die sie enthalten | |
EP1960387B1 (de) | Isochinolin- und benzo[h]isochinolin-derivate, herstellung und therapeutische verwendung davon als antagonisten des histamin-h3-rezeptors | |
EP0004494B1 (de) | 1,3-Dihydro-3-(1-(2-(2,3-dihydro-1,4-benzodioxin-2-yl)2-hydroxy-äthyl)piperidin-4-yl)2H-indol-2-on Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zubereitungen | |
FR2758329A1 (fr) | Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique | |
FR2751650A1 (fr) | Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique | |
EP0301936B1 (de) | Piperidin-Derivate, deren Herstellung und deren Verwendung als Heilmittel | |
DE69813886T2 (de) | Naphthalin derivate | |
EP0718307A2 (de) | 1-Oxo-2-(phenylsulfonyl-amino)-pentylpiperidine Derivate, Verfahren zu ihrer Herstellung und ihre therapeutische Verwendung | |
FR2753970A1 (fr) | Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique | |
EP0971916A1 (de) | N-(arginyl)benzensulfonamidderivate und ihre verwendung als antithrombotische mittel | |
EP1385858B1 (de) | Neue 5-thio-ss-d-xylopyranosidderivate, verfahren zu deren herstellung, diese enthaltende pharmazeutische zusammensetzungen und deren therapeutische verwendung | |
FI105270B (fi) | Menetelmä terapeuttisesti käyttökelpoisten oktahydro-1H-1-pyrindiini-4,5,6,7-terolien valmistamiseksi | |
FR2783521A1 (fr) | Derives de n-(arginyl) benzenesulfonamide, leur preparation et leur application en therapeutique | |
EP0946517A1 (de) | N-(imidazolylbutyl)-phenylsulfonamidderivate mit antithrombotischer aktivität | |
FR2681320A1 (fr) | Derives de n-(4,7dimethoxyindan-2-yl)-1-(phenylcarbonyl)-n-propyl-piperidine-4-methanamine, leur preparation et leur application en therapeutique. | |
EP0522914A1 (de) | 2-Piperidinylpyrimidin-4-Carboxamidderivate, deren Herstellung und deren Verwendung als Heilmittel | |
EP0106860B1 (de) | Karbonsäureamidguanidine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19991020 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20011002 |